Resources Library

EVERSANA’s deep bench of oncology experts leverage their extensive industry experience to inform strategies and deliver services that pave the way to commercial success. In an effort to share expert knowledge and help manufacturers understand the complexities of commercialization for new oncology therapies, EVERSANA developed a robust library of resources.

Watch recordings from industry-leading conferences, download white papers and review recent media publications.

Engaging Oncology Patients and Providers in the Age of COVID and Beyond 詳細情報
A PARTNERSHIP Q&A WITH EVERSANA AND SHORLA PHARMA 詳細情報
NEXT GEN COMMERCIALIZATION MODEL FOR ONCOLOGY 詳細情報
ADDRESSING UNMET MEDICAL NEEDS THROUGH BOLD INNOVATION 詳細情報
DRIVING COMMERCIAL EXCELLENCE FOR CAR-T 詳細情報
Commercialization Strategies in Oncology — The Right Partner Can Reduce Risk and Boost Rewards 詳細情報
CASE STUDY: LAUNCHING A NEW THERAPY FOR BREAST CANCER 詳細情報
Case Study: Patient Affordability Programs 詳細情報
Case Study: High-Tech Medical Information Services 詳細情報
Pivot Pros: How EVERSANA Course Corrected When the Market Changed 詳細情報
The Expanding Oncology Market Prompts Reevaluation of Field Team Training Procedures and Skill Set to Impact Frontline Success 詳細情報
Accelerated Approval Pathways: Manufacturers Left to Grapple With Risk Versus Reward 詳細情報
Point of Attack: Developing a Targeted Oncology Account Engagement Strategy and Tactical Platform 詳細情報
Bringing a CPT Code to Life to Help in the Fight Against Cancer 詳細情報
Reversing the Complexity of Oncology Commercialization: How to solve for launch challenges in a chaotic ecosystem 詳細情報
Next Gen Commercialization: Accelerating Patient Access to Life-Changing Therapies 詳細情報

New Published ASCO Journal Abstracts

Jonathan Kish, General Manager, Real Word Evidence, is a versed expert in Data and Analytics and oncology. He recently demonstrated the value of Real World Evidence in understanding cancer patients’ journeys in his latest abstracts published in the ASCO Journal.

NAVLIN Insights delivers the most innovative market research solutions for oncology manufacturers, from pipeline to loss of exclusivity. Our proprietary insights, which are derived from an unrivaled expert panel network, are combined with an advanced set of methods, frameworks and novel solutions to provide competitive intelligence, insights and strategic recommendations to support the best possible access for your therapy.

Market Access
Monitor key trends in commercial and government markets to understand how payers are managing access to oncolytics relative to other therapeutic areas.
Brand Access
Assess the current and future access environment within a specific cancer type, supporting brand strategies for in-line brands and pipeline assets.
Account Access
Benchmark company performance against competitors of competencies and attributes that promote stronger relationships with cancer centers and oncology group practices.
Account Access
Provide insights on enrollment trends and business strategies of leading cancer centers to support development of effective business and account plans.
Patient Access
Benchmark oncology patient services programs on levels of user importance/value, use, and satisfaction to identify operating gaps and highlight industry best practices, allowing companies to improve patient access to therapy.
Custom Access
Tap into our panel of payer and leading oncology group executives, as well as practicing oncologists to answer your specific business questions.

Featured Content

Payer Oncology Access Management in 2022

Posted on 11月 3, 2022 11/3/22

Payers balance the severity of disease with the need to control high-dollar utilization. As pharmacy spend continues to rise, payers are seeking ways to manage costs in the highest cost therapeutic areas, including oncology. While there is appetite to manage access for both oral and office-administered oncology agents, payers struggle with which tactics to implement without sacrificing patient outcomes. Pharmaceutical companies should expect to see changes in payer management for oncology over the next 2-3 years. In a recent article, the NAVLIN Insights team outlines payer access management in oncology today and takes a closer look at how access will evolve in the coming years, including the impact of the Inflation Reduction Act and which brands may […]

Solving the Wastage Challenge Through Predictive Analytics and Modeling

Posted on 4月 18, 2023 4/18/23

“Solving the Wastage Challenge Through Predictive Analytics and Modeling,” authored by John Chatas, Principal, Specialty Consulting, EVERSANA and Lee Ann Steadman, Senior Vice President, Specialty Consulting, EVERSANA explores how legislative changes like the Wastage Reduction Act are driving pharma companies to find innovative ways to minimize product wastage & avoid costly fines. EVERSANA’s #SpecialtyConsulting supports pharma companies through modeling and predictive forecasting to avoid excessive #productwastage and high-priced penalties. Learn more about how our experts help manufacturers pinpoint their products’ “sweet spot” for practical and economical storing and administering by downloading the article now. Complete the form below to download the full article.

Disease awareness is an essential component to successful commercialization, and our award-winning agency, EVERSANA INTOUCH, has mastered the communication complexity of oncology. Learn why they are the trusted partner for oncology manufacturers.

Case Study: It’s Time to #OvaryAct
Awareness about ovarian cancer was lacking. We changed that in a big way.
詳細情報
#OvaryAct GIFS Making a Difference in Patients' Lives
Real, personal stories make connections to empower patients and caregivers.
詳細情報
#OvaryAct: When the Magic Happens
Capturing brilliance, sense of hope, energy and strength from a community.
詳細情報
Telehealth's Vital Role in Oncology
Telehealth can’t be underestimated as a new model to improve patient care.
詳細情報
#EraseTheLine of Care Inequality
Launching the world's first digital platform designed for Black women by Black women.
詳細情報
#ERASETHELINE Short-Listed for Prestigious D&AD Award
Removing barriers to quality care with a smart and compelling campaign.
詳細情報
#ERASETHELINE MM+M Awards Best in Show 2022 Titanium Recipient
The line that slashes through the equal sign is the ugliest blemish on all healthcare, symbolizing the many racial and gender disparities that impact African American women.
詳細情報
Oncology is Increasingly Competitive – Here’s How to Stand Out
mart oncology brands understand that the need to combine three things to succeed: Positioning, Storytelling and Targeting.
詳細情報
The Necessity of Mapping the Tumor Journey for Oncology Marketers
Oncology marketing efforts must adapt to the changing landscape by mapping Dx and Tx journeys through the unique lens of the tumor itself.
詳細情報